Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bafetinib in Relapsed or Refractory B-CLL
NCT01144260Phase 2Completed
- Sponsor
- LadRx
- Start
- Jun 2010
- Primary completion
- Dec 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bafetinib in chronic lymphocytic leukemia (CLL), sponsored by LadRx. Primary endpoint: Response Rate (Complete and Partial) up to 6 months. Started Jun 2010; status: completed.
02
Drugs
bafetinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01144260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144260.